Market Research

Orphan Drugs Market (Disease Type: Oncology, Gastrointestinal, Pulmonary, Neurology, Hematology, Cardiovascular, Metabolic Disorders, Endocrinology, Infectious Diseases, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20

Best Price Guarantee Length Publisher Published Date SKU
from $5,795 199 Pages Transparency Market Research Pvt. Ltd. April, 2024 TNPR18827838
Best Price Guarantee
Price from $5,795
Length 199 Pages
Publisher Transparency Market Research Pvt. Ltd.
Published Date April, 2024
SKU TNPR18827838

Orphan Drugs Market (Disease Type: Oncology, Gastrointestinal, Pulmonary, Neurology, Hematology, Cardiovascular, Metabolic Disorders, Endocrinology, Infectious Diseases, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034


Orphan Drugs Market – Scope of Report

TMR’s report on the global orphan drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global orphan drugs market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global orphan drugs market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the orphan drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global orphan drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global orphan drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global orphan drugs market.

The report delves into the competitive landscape of the global orphan drugs market. Key players operating in the global orphan drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global orphan drugs market profiled in this report.

Key Questions Answered in Global orphan drugs Market Report
  • What is the sales/revenue generated by orphan drugs across all regions during the forecast period?
  • What are the opportunities in the global orphan drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Orphan Drugs Market – Research Objectives and Research Approach

The comprehensive report on the global orphan drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global orphan drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global orphan drugs market.


1. Preface
  1.1. Market Definition and Scope
  1.2. Market Segmentation
  1.3. Key Research Objectives
  1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Orphan Drugs Market
4. Market Overview
  4.1. Introduction
  4.1.1. Product Definition
  4.1.2. Industry Evolution / Developments
  4.2. Overview
  4.3. Market Dynamics
  4.3.1. Drivers
  4.3.2. Restraints
  4.3.3. Opportunities
  4.4. Global Orphan Drugs Market Analysis and Forecast, 2020-2034
5. Key Insights
  5.1. Pipeline Analysis
  5.2. Key Product/Brand Analysis
  5.3. Key Mergers & Acquisitions
  5.4. COVID-19 Pandemic Impact on Industry
6. Global Orphan Drugs Market Analysis and Forecast, by Disease Type
  6.1. Introduction and Definitions
  6.2. Key Findings/Developments
  6.3. Market Value Forecast, by Disease Type, 2020-2034
  6.3.1. Oncology
  6.3.2. Gastrointestinal
  6.3.3. Pulmonary
  6.3.4. Neurology
  6.3.5. Hematology
  6.3.6. Cardiovascular
  6.3.7. Metabolic Disorders
  6.3.8. Endocrinology
  6.3.9. Infectious Diseases
  6.3.10. Others
  6.4. Market Attractiveness, by Disease Type
7. Global Orphan Drugs Market Analysis and Forecast, by Indicator
  7.1. Introduction and Definitions
  7.2. Key Findings/Developments
  7.3. Market Value Forecast, by Indicator, 2020-2034
  7.3.1. Biologic
  7.3.2. Non-biologic
  7.4. Market Attractiveness, by Indicator
8. Global Orphan Drugs Market Analysis and Forecast, By Distribution Channel
  8.1. Introduction and Definitions
  8.2. Key Findings/Developments
  8.3. Market Value Forecast, By Distribution Channel, 2020-2034
  8.3.1. Hospital Pharmacies
  8.3.2. Specialty Pharmacies
  8.3.3. Retail Pharmacies
  8.3.4. Others
  8.4. Market Attractiveness, By Distribution Channel
9. Global Orphan Drugs Market Analysis and Forecast, by Region
  9.1. Key Findings
  9.2. Market Value Forecast, by Region, 2020-2034
  9.2.1. North America
  9.2.2. Europe
  9.2.3. Asia Pacific
  9.2.4. Latin America
  9.2.5. Middle East & Africa
  9.3. Market Attractiveness, by Region
10. North America Orphan Drugs Market Analysis and Forecast
  10.1. Introduction
  10.1.1. Key Findings
  10.2. Market Value Forecast, by Disease Type, 2020-2034
  10.2.1. Oncology
  10.2.2. Gastrointestinal
  10.2.3. Pulmonary
  10.2.4. Neurology
  10.2.5. Hematology
  10.2.6. Cardiovascular
  10.2.7. Metabolic Disorders
  10.2.8. Endocrinology
  10.2.9. Infectious Diseases
  10.2.10. Others
  10.3. Market Attractiveness, by Disease Type
  10.4. Market Value Forecast, by Indicator, 2020-2034
  10.4.1. Biologic
  10.4.2. Non-biologic
  10.5. Market Attractiveness, by Indicator
  10.6. Market Value Forecast, By Distribution Channel, 2020-2034
  10.6.1. Hospital Pharmacies
  10.6.2. Specialty Pharmacies
  10.6.3. Retail Pharmacies
  10.6.4. Others
  10.7. Market Attractiveness, By Distribution Channel
  10.8. Market Value Forecast, by Country/Sub-region, 2020-2034
  10.8.1. U.S.
  10.8.2. Canada
  10.9. Market Attractiveness Analysis
  10.9.1. By Disease Type
  10.9.2. By Indicator
  10.9.3. By Distribution Channel
  10.9.4. By Country
11. Europe Orphan Drugs Market Analysis and Forecast
  11.1. Introduction
  11.1.1. Key Findings
  11.2. Market Value Forecast, by Disease Type, 2020-2034
  11.2.1. Oncology
  11.2.2. Gastrointestinal
  11.2.3. Pulmonary
  11.2.4. Neurology
  11.2.5. Hematology
  11.2.6. Cardiovascular
  11.2.7. Metabolic Disorders
  11.2.8. Endocrinology
  11.2.9. Infectious Diseases
  11.2.10. Others
  11.3. Market Attractiveness, by Disease Type
  11.4. Market Value Forecast, by Indicator, 2020-2034
  11.4.1. Biologic
  11.4.2. Non-biologic
  11.5. Market Attractiveness, by Indicator
  11.6. Market Value Forecast, By Distribution Channel, 2020-2034
  11.6.1. Hospital Pharmacies
  11.6.2. Specialty Pharmacies
  11.6.3. Retail Pharmacies
  11.6.4. Others
  11.7. Market Attractiveness, By Distribution Channel
  11.8. Market Value Forecast, by Country/Sub-region, 2020-2034
  11.8.1. Germany
  11.8.2. U.K.
  11.8.3. France
  11.8.4. Italy
  11.8.5. Spain
  11.8.6. Rest of Europe
  11.9. Market Attractiveness Analysis
  11.9.1. By Disease Type
  11.9.2. By Indicator
  11.9.3. By Distribution Channel
  11.9.4. By Country/Sub-region
12. Asia Pacific Orphan Drugs Market Analysis and Forecast
  12.1. Introduction
  12.1.1. Key Findings
  12.2. Market Value Forecast, by Disease Type, 2020-2034
  12.2.1. Oncology
  12.2.2. Gastrointestinal
  12.2.3. Pulmonary
  12.2.4. Neurology
  12.2.5. Hematology
  12.2.6. Cardiovascular
  12.2.7. Metabolic Disorders
  12.2.8. Endocrinology
  12.2.9. Infectious Diseases
  12.2.10. Others
  12.3. Market Attractiveness, by Disease Type
  12.4. Market Value Forecast, by Indicator, 2020-2034
  12.4.1. Biologic
  12.4.2. Non-biologic
  12.5. Market Attractiveness, by Indicator
  12.6. Market Value Forecast, By Distribution Channel, 2020-2034
  12.6.1. Hospital Pharmacies
  12.6.2. Specialty Pharmacies
  12.6.3. Retail Pharmacies
  12.6.4. Others
  12.7. Market Attractiveness, By Distribution Channel
  12.8. Market Value Forecast, by Country/Sub-region, 2020-2034
  12.8.1. China
  12.8.2. Japan
  12.8.3. India
  12.8.4. Australia & New Zealand
  12.8.5. Rest of Asia Pacific
  12.9. Market Attractiveness Analysis
  12.9.1. By Disease Type
  12.9.2. By Indicator
  12.9.3. By Distribution Channel
  12.9.4. By Country/Sub-region
13. Latin America Orphan Drugs Market Analysis and Forecast
  13.1. Introduction
  13.1.1. Key Findings
  13.2. Market Value Forecast, by Disease Type, 2020-2034
  13.2.1. Oncology
  13.2.2. Gastrointestinal
  13.2.3. Pulmonary
  13.2.4. Neurology
  13.2.5. Hematology
  13.2.6. Cardiovascular
  13.2.7. Metabolic Disorders
  13.2.8. Endocrinology
  13.2.9. Infectious Diseases
  13.2.10. Others
  13.3. Market Attractiveness, by Disease Type
  13.4. Market Value Forecast, by Indicator, 2020-2034
  13.4.1. Biologic
  13.4.2. Non-biologic
  13.5. Market Attractiveness, by Indicator
  13.6. Market Value Forecast, By Distribution Channel, 2020-2034
  13.6.1. Hospital Pharmacies
  13.6.2. Specialty Pharmacies
  13.6.3. Retail Pharmacies
  13.6.4. Others
  13.7. Market Attractiveness, By Distribution Channel
  13.8. Market Value Forecast, by Country/Sub-region, 2020-2034
  13.8.1. Brazil
  13.8.2. Mexico
  13.8.3. Rest of Latin America
  13.9. Market Attractiveness Analysis
  13.9.1. By Disease Type
  13.9.2. By Indicator
  13.9.3. By Distribution Channel
  13.9.4. By Country/Sub-region
14. Middle East & Africa Orphan Drugs Market Analysis and Forecast
  14.1. Introduction
  14.1.1. Key Findings
  14.2. Market Value Forecast, by Disease Type, 2020-2034
  14.2.1. Oncology
  14.2.2. Gastrointestinal
  14.2.3. Pulmonary
  14.2.4. Neurology
  14.2.5. Hematology
  14.2.6. Cardiovascular
  14.2.7. Metabolic Disorders
  14.2.8. Endocrinology
  14.2.9. Infectious Diseases
  14.2.10. Others
  14.3. Market Attractiveness, by Disease Type
  14.4. Market Value Forecast, by Indicator, 2020-2034
  14.4.1. Biologic
  14.4.2. Non-biologic
  14.5. Market Attractiveness, by Indicator
  14.6. Market Value Forecast, By Distribution Channel, 2020-2034
  14.6.1. Hospital Pharmacies
  14.6.2. Specialty Pharmacies
  14.6.3. Retail Pharmacies
  14.6.4. Others
  14.7. Market Attractiveness, By Distribution Channel
  14.8. Market Value Forecast, by Country/Sub-region, 2020-2034
  14.8.1. GCC Countries
  14.8.2. South Africa
  14.8.3. Rest of Middle East & Africa
  14.9. Market Attractiveness Analysis
  14.9.1. By Disease Type
  14.9.2. By Indicator
  14.9.3. By Distribution Channel
  14.9.4. By Country/Sub-region
15. Competition Landscape
  15.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  15.2. Market Share Analysis, by Company (2023)
  15.3. Company Profiles
  15.3.1. Novartis AG
  15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
  15.3.1.2. Product Portfolio
  15.3.1.3. Financial Overview
  15.3.1.4. SWOT Analysis
  15.3.1.5. Strategic Overview
  15.3.2. Bristol-Myers Squibb Company
  15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
  15.3.2.2. Product Portfolio
  15.3.2.3. Financial Overview
  15.3.2.4. SWOT Analysis
  15.3.2.5. Strategic Overview
  15.3.3. Celgene Corporation
  15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
  15.3.3.2. Product Portfolio
  15.3.3.3. Financial Overview
  15.3.3.4. SWOT Analysis
  15.3.3.5. Strategic Overview
  15.3.4. F. Hoffmann-La Roche Ltd.
  15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
  15.3.4.2. Product Portfolio
  15.3.4.3. Financial Overview
  15.3.4.4. SWOT Analysis
  15.3.4.5. Strategic Overview
  15.3.5. Pfizer, Inc.
  15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
  15.3.5.2. Product Portfolio
  15.3.5.3. Financial Overview
  15.3.5.4. SWOT Analysis
  15.3.5.5. Strategic Overview
  15.3.6. Sanofi S.A.
  15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
  15.3.6.2. Product Portfolio
  15.3.6.3. Financial Overview
  15.3.6.4. SWOT Analysis
  15.3.6.5. Strategic Overview
  15.3.7. Alexion Pharmaceuticals, Inc.
  15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
  15.3.7.2. Product Portfolio
  15.3.7.3. Financial Overview
  15.3.7.4. SWOT Analysis
  15.3.7.5. Strategic Overview
  15.3.8. Eli Lilly and Company
  15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
  15.3.8.2. Product Portfolio
  15.3.8.3. Financial Overview
  15.3.8.4. SWOT Analysis
  15.3.8.5. Strategic Overview
  15.3.9. Novo Nordisk A/S
  15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
  15.3.9.2. Product Portfolio
  15.3.9.3. Financial Overview
  15.3.9.4. SWOT Analysis
  15.3.9.5. Strategic Overview
  15.3.10. AstraZeneca plc
  15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
  15.3.10.2. Product Portfolio
  15.3.10.3. Financial Overview
  15.3.10.4. SWOT Analysis
  15.3.10.5. Strategic Overview
  15.3.11. Eisai Co., Ltd.
  15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
  15.3.11.2. Product Portfolio
  15.3.11.3. Financial Overview
  15.3.11.4. SWOT Analysis
  15.3.11.5. Strategic Overview
  15.3.12. Daiichi Sankyo Company Limited
  15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
  15.3.12.2. Product Portfolio
  15.3.12.3. Financial Overview
  15.3.12.4. SWOT Analysis
  15.3.12.5. Strategic Overview
  15.3.13. Bayer AG
  15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
  15.3.13.2. Product Portfolio
  15.3.13.3. Financial Overview
  15.3.13.4. SWOT Analysis
  15.3.13.5. Strategic Overview
  15.3.14. GlaxoSmithKline plc
  15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
  15.3.14.2. Product Portfolio
  15.3.14.3. Financial Overview
  15.3.14.4. SWOT Analysis
  15.3.14.5. Strategic Overview
  15.3.15. Merck & Co., Inc.
  15.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
  15.3.15.2. Product Portfolio
  15.3.15.3. Financial Overview
  15.3.15.4. SWOT Analysis
  15.3.15.5. Strategic Overview
  15.3.16. Johnson & Johnson
  15.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
  15.3.16.2. Product Portfolio
  15.3.16.3. Financial Overview
  15.3.16.4. SWOT Analysis
  15.3.16.5. Strategic Overview
  15.3.17. Biogen, Inc.
  15.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)
  15.3.17.2. Product Portfolio
  15.3.17.3. Financial Overview
  15.3.17.4. SWOT Analysis
  15.3.17.5. Strategic Overview
  15.3.18. Shire plc
  15.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)
  15.3.18.2. Product Portfolio
  15.3.18.3. Financial Overview
  15.3.18.4. SWOT Analysis
  15.3.18.5. Strategic Overview
  15.3.19. Amgen, Inc.
  15.3.19.1. Company Overview (HQ, Business Segments, Employee Strength)
  15.3.19.2. Product Portfolio
  15.3.19.3. Financial Overview
  15.3.19.4. SWOT Analysis
  15.3.19.5. Strategic Overview

$5,795
$8,795
$11,795

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings